Samsung Bioepis Announces First Real-World Data on RENFLEXIS® (infliximab-abda) with IBD patients from Veterans Affairs Healthcare System at the American College of Gastroenterology (ACG) 2020
October 26, 2020 08:00 ET
|
Samsung Bioepis
Switching from reference infliximab or infliximab-dyyb to RENFLEXIS® (infliximab-abda) demonstrated comparable efficacy and safety in IBD patients registered to VA Healthcare SystemContinuation rates...
Samsung Bioepis Receives European Commission Approval for AYBINTIO® (Bevacizumab)
August 20, 2020 04:47 ET
|
Samsung Bioepis
AYBINTIO® is approved for the treatment of the same types of cancer as reference bevacizumab (AVASTIN®i)AYBINTIO® is Samsung Bioepis’ fifth biosimilar to be approved by the European Commission ...
Samsung Bioepis Receives Positive CHMP Opinion for AYBINTIO® (Bevacizumab)
June 26, 2020 07:12 ET
|
Samsung Bioepis
AYBINTIO®, a biosimilar candidate referencing Avastin®i (bevacizumab), is Samsung Bioepis’ second oncology biosimilar to be recommended for marketing authorization by the European Medicines...